Sichuan Biokin Pharmaceutical Co., Ltd. (Ticker: 2615 HK) is a Chinese biopharmaceutical company that develops and manufactures pharmaceuticals, including biologics such as antibody-drug conjugates (ADCs) for oncology, generics, and traditional Chinese medicines covering anesthesia, anti-infection, pediatrics, and chronic diseases. It operates an integrated R&D, manufacturing, and commercialization platform with global reach, including a U.S. subsidiary SystImmune for ADC development, and is already listed on the Shanghai STAR Market (Ticker: 688506 CH) since 2023.

The company plans to list H-shares on the Hong Kong Stock Exchange Main Board on November 17, 2025, offering 8.63 million primary shares at HKD 347.50-389.00, to raise up to HKD 3.36 billion (USD 432 million). Post-IPO market capitalization is about USD 21 billion). Proceeds will be used for R&D, production capacity expansion, working capital, and strategic acquisitions. Joint sponsors and lead underwriters are J.P. Morgan Securities (Asia Pacific) Limited, Goldman Sachs (Asia) L.L.C., and CLSA Limited. Cornerstone investors include Bristol-Myers Squibb and OrbiMed.